Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(66.7%)
N/A
1(33.3%)
3Total
Phase 2(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07476625Not ApplicableNot Yet Recruiting

Efficacy and Safety of Thalidomide for Pediatric PFAPA Syndrome

Role: lead

NCT04218565Phase 2Terminated

Golimumab for the Treatment of Refractory Behcet's Uveitis

Role: lead

NCT03554161Phase 2Terminated

Tocilizumab for the Treatment of Refractory Behcet's Uveitis

Role: lead

All 3 trials loaded